PI3K/AKT Pathway Emerges as Central Target for Ischemic Stroke Neuroprotection

Ischemic stroke remains a leading cause of death and disability worldwide, yet approved treatments are limited to thrombolysis and thrombectomy, both constrained by narrow therapeutic windows. This comprehensive review, published in Neural Regeneration Research, synthesizes evidence from PubMed, Embase, MEDLINE, and Web of Science (through May 2024) to map the PI3K/AKT signaling pathway as a master regulator of stroke pathobiology and a compelling drug target.

The review first delineates five interconnected pathological cascades triggered by cerebral ischemia. Energy depletion releases excitatory amino acids (glutamate, aspartate) into synaptic spaces, driving excitotoxic neuronal death. This is compounded by intracellular calcium overload, which activates phospholipases and NOS, producing reactive oxygen species (ROS) and impairing mitochondrial ATP synthesis. Inflammatory infiltration—mediated by neutrophils, microglia, and astrocytes releasing TNF-α, interleukins, and NF-κB—amplifies tissue damage. Oxidative stress from ROS overwhelms antioxidant enzymes (SOD, CAT, GSH-Px), increasing blood-brain barrier permeability and triggering apoptosis, predominantly in the ischemic penumbra where caspase activation executes programmed cell death.

PI3K/AKT sits at the intersection of all five mechanisms. The pathway—comprising three PI3K classes with distinct substrates and the three AKT isoforms (AKT1 for growth, AKT2 for metabolism, AKT3 for brain development)—converts PIP2 to PIP3, activating downstream nodes including mTOR (autophagy and protein synthesis), NF-κB (inflammation), NRF2 (antioxidant defense), BCL-2 (apoptosis suppression), and eNOS (vascular protection). Endogenous regulators include miRNAs (miR-221, miR-130a, miR-124, miR-18b, miR-122, miR-22) that modulate PTEN-PI3K/AKT signaling, and lncRNAs such as SNHG12 whose silencing reduces apoptosis and autophagy.

Among exogenous agents, natural products receive extensive coverage. Flavonoids, quinones, alkaloids, phenylpropanoids, phenols, terpenoids, and iridoids all demonstrate preclinical neuroprotection by activating PI3K/AKT and its downstream effectors in MCAO rodent models and oxygen-glucose deprivation cell systems. Novel therapeutic modalities—electroacupuncture and mesenchymal stem cell (including bone marrow- and olfactory mucosa-derived MSC) therapies—also activate PI3K/AKT, offering rehabilitation potential beyond acute pharmacotherapy.

The authors highlight key unresolved challenges: the direct regulatory mechanisms linking specific drugs to PI3K/AKT remain incompletely characterized, and virtually no PI3K/AKT-targeted neuroprotective agents have successfully completed clinical translation. They call for mechanistic studies clarifying isoform-specific PI3K/AKT actions in stroke and for translational pipelines that bridge robust preclinical findings to human trials.